Home
Summary
Scientific Results
Indication Fields
    Tumorous Diseases
      • Human Investigations
        - Prostate Tumor
        - Breast Tumor
        - Lung Tumor
        - Other Tumor Types
      • Prevention
    Diabetes
The Inventor
Publications
Conferences
Professional Opinions
Contacts
Tumorous Diseases

In early 90s, Gabor Somlyai reported for the first time the inhibitory effect of decreased deuterium concentration on the growth of different tumorous cell lines in vitro and in vivo. The effect of gradual depletion of deuterium content of the culture media on tumor cell proliferation was investigated on ovarian and breast carcinoma. It was found that in these cell cultures DDW induced significant inhibition of tumor growth. Deuterium depletion repressed cell division in plants and suppressed certain genes, involved in tumour formation.

The effect of DDW on tumor growth was investigated in immunosupressed mice transplanted with MDA-MB-231 and MCF-7 human breast and PC-3 prostate tumor. DDW halted or reversed tumor growth in vivo.

In animal studies carried out with dogs and cats having different spontaneous tumors (breast, rectum, lymphoid leucosis, epithelioma, sarcomatoid tumors and melanoma), in spite of the various diagnoses, all the tumors responded favorably to DDW treatment.

Results of prospective and retrospective human clinical studies supported the preclinical findings.

The effect of DDW on prostate cancer was evaluated in a phase 2 clinical study. Clinical symptoms ceased at a significantly higher rate during the trial, and the average survival time was significantly longer in the treated group at the one year follow-up.

In retrospective studies conducted with patients with stage IV breast tumor and lung cancer, the evaluation showed that the patients achieved remarkably longer survival times as a result of DDW incorporated into the oncological treatment regimes. In patients who were in remission when they started to consume DDW, the current relapse rate decreased significantly.

Experience has shown that the results (median survival, progression-free interval, etc.) that can be achieved with the conventional oncotherapies can be multiplied by the use of deuterium depletion as supportive therapy.

Reference: Somlyai et al.: FEBS Letter (1993) 317, 1-4.
Advertisement:
 
Source: hyd.hu 
 
Website by: Bexmon™ Marketing. | Host by: Bexhost.com
Powered by: Pagelex.com